Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.16 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
News headline image
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle ↗
Hims & Hers Health is on deck to report its fourth-quarter earnings late Monday. Here's what to expect. 
Via Investor's Business Daily
News headline image
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk ↗
Via The Motley Fool
News headline image
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs ↗
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
News headline image
Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations. 
Via The Motley Fool
News headline image
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Why Novo Nordisk Stock Popped on Friday ↗
Via The Motley Fool
News headline image
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes ↗
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi. 
Via Benzinga
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage ↗
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. 
Via Investor's Business Daily
News headline image
Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News ↗
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime. 
Via The Motley Fool
News headline image
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
2 Important Insights From Novo Nordisk's Earnings Call ↗
Via The Motley Fool
News headline image
A Closer Look at Novo Nordisk's Options Market Dynamics ↗
 
Via Benzinga
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages ↗
Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led to a failed Phase 3 trial. 
Via Benzinga
Topics Lawsuit
News headline image
Digging Into What Hershey and Eli Lilly Told Investors ↗
Via The Motley Fool
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
How Is The Market Feeling About Novo Nordisk? ↗
 
Via Benzinga
News headline image
Why Novo Nordisk Stock Keeps Going Down ↗
Via The Motley Fool
News headline image
3 Hot Stocks That Have Already Doubled in 2025 ↗
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year. 
Via The Motley Fool
News headline image
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management. 
Via Benzinga
News headline image
These 3 Stocks Just Announced Major Dividend Hikes
Via MarketBeat
News headline image
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low? 
Via MarketBeat
News headline image
NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon ↗
Via The Motley Fool
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.